Mass balance, metabolic disposition, and pharmacokinetics of a single IV dose of [14C]CA102N in HT-29 xenograft athymic nude mice
2024

Study of CA102N: A New Cancer Drug in Mice

Sample size: 48 publication 10 minutes Evidence: moderate

Author Information

Author(s): Tchaparian Eskouhie, Lin Hua-Yang, Chen Yuchih, Hunter J. Neil, Yin Sindy, Ng Huey, Wu Albert

Primary Institution: Holy Stone Healthcare

Hypothesis

The study aims to evaluate the pharmacokinetics, biodistribution, metabolism, and tumor permeability of CA102N in xenograft mice.

Conclusion

The study demonstrated that CA102N is primarily eliminated through metabolism and shows significant tumor retention, supporting its potential as an anticancer therapy.

Supporting Evidence

  • 94.9% of the administered dose was recovered at 240 hours post-dose.
  • 77% of the dose was eliminated through urine.
  • CA102N showed a two-phase pharmacokinetic profile with a half-life of 22 hours.
  • The maximum concentration of CA102N was reached at 0.5 hours post-dose.
  • Two major metabolites were identified: H-Nim-disaccharide and H-Nim-tetrasaccharide.

Takeaway

Researchers gave a new cancer drug to mice and found that it stays in the tumors longer, which could help treat cancer better.

Methodology

The study used liquid scintillation counting, HPLC-MS, and quantitative whole-body autoradiography to analyze pharmacokinetics and metabolism.

Limitations

The small number of mice per time point in the biodistribution assessment may limit the statistical power.

Participant Demographics

Female BALB/c athymic (nu+/nu+) mice were used in the study.

Digital Object Identifier (DOI)

10.3389/fphar.2024.1440679

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication